Sanara MedTech Inc.(SMTI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Sanara MedTech Inc. (SMTI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SMTI at 38.0/100 on a 32-signal composite quality model, placing it at rank #2,215 of 2,962 stocks — the bottom half of the AI-ranked universe. SMTI scores in the top quartile across revenue growth (84.3). Areas of concern include balance sheet strength (6.0) and profitability (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Sanara MedTech Inc. reports quarterly revenue of $28.1M, net income of $-452.9K, an operating margin of 6.3%. Top institutional holders of SMTI by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, ROYAL BANK OF CANADA, based on the most recent SEC filings. SMTI trades on the Nasdaq exchange and files with the SEC under CIK 714256. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sanara MedTech Inc. directly from SEC EDGAR.